Cardiovascular Drugs and Therapy

, Volume 4, Issue 1, pp 237–242 | Cite as

Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension

  • Gary H. Gibbons
  • Victor J. Dzau
Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects


The pathogenesis of hypertension is associated with a remodeling of vascular structure. Folkow has postulated that the decreased luminal area and thickened medial layer in hypertensive vessels enhances the vasoconstrictive response to vasoactive agents. It is hypothesized that this increase in vascular reactivity may serve to perpetuate hypertension. A growing body of evidence suggests that autocrineparacrine vasoactive substances and growth factors modulate vascular structure in hypertension. We speculate that therapeutic interventions that normalize blood pressure as well as reverse the vascular remodeling process may have special clinical value. The role of the paracrine renin-angiotensin system and angiotensin converting enzyme inhibitors in hypertension is discussed in this context.

Key Words

angiotensin vascular smooth muscle hypertension converting enzyme inhibitors hypertrophy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers.Circ Res 1978;43:854–864.PubMedGoogle Scholar
  2. 2.
    Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.Hypertension 1987;9:178–187.PubMedGoogle Scholar
  3. 3.
    Barrett TB, Sampson P, Owens GK, Schwartz SM, Benditt EP. Polyploid nuclei in human artery wall smooth muscle cells.Proc Natl Acad Sci USA 1983;80:882–885.PubMedGoogle Scholar
  4. 4.
    Chobanian AV, Lichtenstein AH, Schwartz JH, Hanspal J, Brecher P. Effects of deoxycorticosterone/salt hypertension on cell ploidy in rat aortic smooth muscle cells.Circulation 1987;75 (Suppl 1):I102–I106.PubMedGoogle Scholar
  5. 5.
    Udenfriend S, Cardinale G, Spector S. Hypertensioninduced vascular fibrosis and its reversal by antihypertensive drugs. In: Laragh JH, Buhler FR, Seldin OW, eds.Frontiers in Hypertension Research. New York: Springer-Verlag 1981.Google Scholar
  6. 6.
    Lockette W, Otsuka Y, Carretero O. The loss of endothelium dependent vascular relaxation in hypertension.Hypertension 1986;8 (Suppl II):II61–II66.PubMedGoogle Scholar
  7. 7.
    Limas C, Westrum B, Limas CJ. Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats.Am J Pathol 1984;117: 360–371.PubMedGoogle Scholar
  8. 8.
    Hazama F, Ozaki T, Shigeru A. Scanning electron microscopic study of endothelial cells of cerebral arteries from spontaneously hypertensive rats.Stroke 1979;10:245–252.PubMedGoogle Scholar
  9. 9.
    Ooneda G. Pathology of stroke.Jpn Circ J 1986;50:1224–1234.PubMedGoogle Scholar
  10. 10.
    Cook TA, Yates PO. A histometric study of cerebral and renal arteries in normotensives and chronic hypertensives.J Pathol 1972;108:129–135.PubMedGoogle Scholar
  11. 11.
    Hollenberg NK. Vasodilators, antihypertensive therapy, and the kidney.Circulation 1987;75 (Suppl V):V39–V42.PubMedGoogle Scholar
  12. 12.
    Sano T, Tarazi RC. Differential structural responses of small resistance vessels to antihypertensive therapy.Circulation 1987;75(3):618–626.PubMedGoogle Scholar
  13. 13.
    Hammond GL, Lai YK, Markert CL. The molecules that initiate cardiac hypertrophy are not species-specific.Science 1982;216:529–531.PubMedGoogle Scholar
  14. 14.
    Vandenburgh H, Kaufman S. In vitro model for stretchinduced hypertrophy of skeletal muscle.Science 1979;203: 265–268.PubMedGoogle Scholar
  15. 15.
    Leung DYM, Glagov S, Mathews MB. Cyclic stretching stimulates synthesis of matrix components by arterial smooth muscle cells in vitro.Science 1976;191:475–477.PubMedGoogle Scholar
  16. 16.
    Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium dependent.Science 1986;231:405–407.PubMedGoogle Scholar
  17. 17.
    Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS. Modulation of vascular smooth muscle contraction by the endothelium.Ann Rev Physiol 1986;48:307–320.Google Scholar
  18. 18.
    Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell.Hypertension 1988;12:530–548.PubMedGoogle Scholar
  19. 19.
    Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature 1988;332:411–415.PubMedGoogle Scholar
  20. 20.
    Lansman JB, Hallam TJ, Rink TJ. Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers.Nature 1987;325:811–813.PubMedGoogle Scholar
  21. 21.
    Olesan SP, Clapham DE, Davies PF. Hemodynamic shear stress activates a K+ current in vascular endothelial cells.Nature 1988;331:168–170.PubMedGoogle Scholar
  22. 22.
    Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb RC. Vasoconstriction: A new activity for platelet-derived growth factor.Science 1986;232:87–90.PubMedGoogle Scholar
  23. 23.
    Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis.Circulation 1988;77 (Suppl I): I4–I13.PubMedGoogle Scholar
  24. 24.
    Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat.J Clin Invest 1984;74:1247–1251.PubMedGoogle Scholar
  25. 25.
    Kawasaki H, Cline WH Jr, Su C. Involvement of the vascular renin-angiotensin system in beta-adrenergic receptormediated facilitation of vascular transmission in spontaneously hypertensive rats.J Pharmacol Exp Ther 1984;231: 23–32.PubMedGoogle Scholar
  26. 26.
    Dzau VJ, Safar ME. Large conduit arteries in hypertension: Role of the vascular renin-angiotensin system.Circulation 1988;77:947–954.PubMedGoogle Scholar
  27. 27.
    Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro.Exp Mol Pathol 1981;35:265–276.PubMedGoogle Scholar
  28. 28.
    Geisterfer AAT, Peach MJ, Owens G. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.Circ Res 1988;62:749–756.PubMedGoogle Scholar
  29. 29.
    Naftilan AJ, Pratt RE, Dzau VJ. Angiotensin II induction ofc-fos, c-myc, and platelet derived growth factor in vascular smooth muscle cells.Clin Res 1988;36:303A.Google Scholar
  30. 30.
    Yamori Y, Mano M, Nara Y, Horie R. Catecholamineinduced polyploidization in vascular smooth muscle cells.Circulation 1987;75 (Suppl I):I92–I95.PubMedGoogle Scholar
  31. 31.
    Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin.Proc Natl Acad Sci USA 1986;83:674–678.PubMedGoogle Scholar
  32. 32.
    Ishimitsu T, Vehara Y, Ishii M, Ikeda T, Matsuoka H, Sugimoto T. Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats.Hypertension 1988;12:46–51.PubMedGoogle Scholar
  33. 33.
    Palmberg L, Claesson H-E, Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle cells.J Cell Sci 1987;88:151–159.PubMedGoogle Scholar
  34. 34.
    Sjölund M, Nilsson J, Palmberg L, Thyberg J. Phenotype modulation in primary cultures of arterial smooth muscle cells: Dual effect of prostaglandin E-I.Differentiation 1984;27:158–162.PubMedGoogle Scholar
  35. 35.
    Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA, Alexander RW. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction.J Clin Invest 1985;75:1083–1086.PubMedGoogle Scholar
  36. 36.
    Freslon JL, Giudicelli JP. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats.Br J Pharmacol 1983;80:533–543.PubMedGoogle Scholar
  37. 37.
    Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure.J Hypertens 1989;7:83–90.PubMedGoogle Scholar
  38. 38.
    Christensen HRL, Nielsen H, Christensen KL, Baandrup U, Jespersen LT, Mulvany MJ. Long-term hypotensive effects of an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: Is there a role for vascular structure?J Hypertens 1988;6 (Suppl 3):S27–S31.Google Scholar
  39. 39.
    Barry DI, Paulson OB, Jarden JO, Juhler M, Graham DI, Strandgaard S. Effects of captopril on cerebral blood flow in normotensive and hypertensive rats.Am J Med 1984;76 (5B):79–85.Google Scholar
  40. 40.
    Unger T, Ganten D, Lang RE, Schölkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.J Cardiovasc Pharmacol 1985;7:36–41.PubMedGoogle Scholar
  41. 41.
    Wilson SK, Solez K, Boitnolt JK, Heptinstall RH. The effects of heparin treatment on hypertensive and vascular lesions in stroke-prone spontaneously hypertensive rats.Am J Pathol 1981;102:62–71.PubMedGoogle Scholar
  42. 42.
    Hoover RL, Rosenberg R, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin: II. In vitro studies.Circ Res 1980;47:578–583.PubMedGoogle Scholar
  43. 43.
    Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin: In vivo studies with anticoagulant and nonanticoagulant heparin.Circ Res 1980;46:625–634.PubMedGoogle Scholar
  44. 44.
    Langford HG, Blaufox D, Oberman A, Hawkins M, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernathy JD, Hotchkiss J, Tyler M. Dietary therapy slows the return of hypertension after stopping prolonged medication.JAMA 1985;753:657–664.Google Scholar
  45. 45.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs.Circulation 1975;51:1107–1113.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Gary H. Gibbons
    • 1
  • Victor J. Dzau
    • 1
  1. 1.Molecular and Cellular Vascular Research Laboratory, Division of Vascular Medicine and Atherosclerosis, Brigham and Women's HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations